In Re Hemex Liquidation Trust

129 B.R. 91, 1991 Bankr. LEXIS 1703, 1991 WL 118565
CourtUnited States Bankruptcy Court, W.D. Louisiana
DecidedJune 28, 1991
Docket19-80153
StatusPublished
Cited by6 cases

This text of 129 B.R. 91 (In Re Hemex Liquidation Trust) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, W.D. Louisiana primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Hemex Liquidation Trust, 129 B.R. 91, 1991 Bankr. LEXIS 1703, 1991 WL 118565 (La. 1991).

Opinion

REASONS FOR DECISION

HENLEY A. HUNTER, Bankruptcy Judge.

This matter came on for a hearing on June 20, 1991, on the Motion of Baxter Healthcare Corporation to Dismiss or Convert. Evidence was adduced and the matter was taken under advisement. For reasons which follow, this case will be dismissed. This is a Core Proceeding pursuant to 28 U.S.C. Section 157(b)(2) inasmuch as it involves the administration of the debtor’s estate under Subsection (A) and other proceedings affecting the adjustment of the debtor-creditor relationship under Subsection (O). This Court has jurisdiction pursuant to 28 U.S.C. Section 1334 and by virtue of the reference by the District Court pursuant to Local District Court Rule 22.1 incorporated into Local Bankruptcy Rule 1.2. No party at interest has sought to withdraw the reference to the Bankruptcy Court, nor has the District Court done so on its own motion. This Court makes the following findings of fact and conclusions of law in accordance with Bankruptcy Rule 7052.

FINDINGS OF FACT AND CONCLUSIONS OF LAW

A. Background

This case was filed as a voluntary case under Chapter 11 on April 9, 1991. Debtor is a liquidating trust which was formed after its predecessor, Hemex Scientific, Inc., sold its entire business to American Hospital Supply Corporation in 1986 pursuant to a document known as an “Assets Purchase Agreement.” The assets of the seller consisted primarily of a patent and FDA approval for the manufacture and *93 sale of the Duramedics TM heart valve. The sale also conveyed Hemex Inc.’s inventory, manufacturing and distribution facilities. The overall sales price was in excess of $40 million dollars. A portion ($4.4 million) of the sales price was reserved under the contract and segregated into two funds; one for $400,000.00, styled the “product liability fund,” and another for $4,000,000, styled the “general liability fund.” Procedures were established for claims against such funds and various dates established for distribution of payments due the seller. Interest payments were made until December of 1989.

Suit was then instituted in the 14th Judicial District Court for Calcasieu Parish for approval of a settlement. The suit originated as a request for instructions concerning a trust and, debtor asserts, was instigated in its name but at the behest of Baxter. The settlement was not approved and the suit has since been amended to seek damages for unfair trade and competitive practices and breach of contract. The suit was removed to the United States District Court for the Western District of Louisiana under Civil Action Number 91- 8042 1 . Baxter filed suit for declaratory and other relief in the Nineteenth Judicial District in Lake County, Illinois under Docket No. 90 MR 609, which was ultimately removed to the United States District Court for the Northern District of Illinois under No. 91C2814. See Exhibits B (1-4); 2

In Debtor’s own words, its existence is described as follows:

“Hemex is a liquidating trust. It formed for three purposes. Firstly Section 11.5 of the Assets Purchase Agreement required Hemex to change its ñamé and suspend operations. Secondly, certain tax laws were scheduled to expire at idle end of calendar 1986, requiring immediate liquidation of the seller. Thirdly, aspects of the sale remained exec-utory and the trust provided a vehicle to enforce those provisions. The trust continued primarily to receive the funds contractually owed to it by Baxter and perform other liquidation functions. Hemex in fact has no routine business. It does not conduct a trade, sell merchandise, or perform services to the public. It has no need for day-to-day employees. It has, however, performed a variety of tasks. These include assisting Baxter in the defense of third-party claims, taking action against the sellers’ former attorney to preserve confidential information, defending claims commenced by Carbomed-ics, Inc., filing tax returns, negotiating with Baxter, dealing with insurers, and obtaining legal advice for it and its beneficiaries. Its attorneys, accountants and consultants provide many of the services. Its co-trustees and beneficiaries also expend significant time and effort for He-mex. It owes a relatively little unsecured debt; however, it is not true that it exists solely at this time to be sued or to sue in a dispute arising from Baxter’s purchase in 1986.” Memorandum in Opposition filed June 17, 1991, page 4.

B. Contentions of the Parties

Baxter seeks alternatively dismissal or conversion alleging (1) that the sole purpose of the filing was the invocation of the automatic stay to frustrate the Illinois litigation; (2) that debtor has no ability to effectuate a plan of reorganization in that it conducts no business and exists only to “wind ... up the affairs of its predecessor” and cannot fund a plan; (3) the case will not result in debtor’s rehabilitation, but *94 rather in losses consisting of the legal fees generated by the filing; and (4) the disputes between debtor, its principal shareholders and Baxter should be resolved in the pre-filing litigation.

In closing argument, counsel for Baxter asserts that debtor improperly sought relief herein inasmuch as the latter’s memorandum filed in connection with this hearing asserts that “[although it has sought this Court's protection in fulfilling its function, it will carry on with or without the protection of the Bankruptcy Court, and a [sic] successfully enforce its claims against Baxter and Carbomedics_” Memorandum in Opposition, page 15.

Debtor, in turn, contends that (1) Baxter lacks standing to challenge the filing of this case, asserting that Baxter is not a party at interest; and (2) this case was, indeed, filed in good faith.

C. Summary of the Evidence

Baxter’s evidence in support of its Motion consisted of its offering of copies of pleadings from the Illinois Court, Exhibits B(l-4). Baxter particularly would have this Court note its argument in B-4 that removal efforts by Hemex and the individual defendants in those proceedings, Russell C. Chambers, Jerome Klawitter, Julius Ta-bin, and Edwin Hunter, are seeking to litigate the matter in Louisiana rather than Illinois, and, therefore, twice sought removal in those proceedings without knowing if Baxter would even oppose the first effort, the latest effort being based on the alleged subject matter jurisdiction of the Federal Court due to the connection to the bankruptcy case. At the conclusion of Baxter’s evidentiary offerings, debtor moved for a directed verdict relying on Federal Rule of Civil Procedure Rule 50. Since that rule relates to jury trials and is inapplicable to Bankruptcy Courts pursuant to Bankruptcy 9014, the motion would have been properly sought as a motion for involuntary dismissal under Rule 41.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
129 B.R. 91, 1991 Bankr. LEXIS 1703, 1991 WL 118565, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-hemex-liquidation-trust-lawb-1991.